| Value | ₹0.25 Cr |
|---|
BSE filing, NSE: INDSWFTLAB. Summary written from the filing by ALFA Finder's alert engine.
Ind-Swift Laboratories Ltd: key numbers
- Share price
- ₹377.40
- Market cap
- ₹3,282 Cr
- Revenue (annual)
- ₹649.1 Cr
- Net profit (annual)
- ₹43.12 Cr
- P/E (TTM)
- 57.2×Sector 46.5×
- Promoter holding
- 42.93%+0.00% QoQ
- FII holding
- 10.78%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ind-Swift Laboratories Ltd
All →Ind-Swift Laboratories Board Meeting Date
Ind-Swift Laboratories Ltd. scheduled a board meeting for October 29, 2026, to consider and approve the standalone and consolidated financial results for the quarter and half-year.
Ind-Swift Laboratories Convertible Warrants
Essix Biosciences Limited acquired 14,00,000 equity shares of Ind-Swift Laboratories Limited following the conversion of fully convertible warrants. The company disclosed this under SEBI regulations.
Ind-Swift Laboratories Capital Structure Change
Ind-Swift Laboratories allotted 14,00,000 equity shares upon conversion of warrants at Rs. 196 each. The allotment follows a previously approved preferential issue.
- Value
- ₹27.44 Cr
Ind-Swift Laboratories Capital Structure Change
Ind-Swift Laboratories allotted 14 lakh equity shares upon converting warrants for Essix Biosciences Limited, receiving ₹20.58 Crore. This increases the company's paid-up equity share capital.
- Value
- ₹20.58 Cr
Ind-Swift Laboratories Annual General Meeting
Ind-Swift Laboratories Limited held its 31st Annual General Meeting on September 30, 2026. Members approved audited financial statements and director appointments.
Ind-Swift Laboratories Other Announcement
Ind-Swift Laboratories Ltd has filed its quarterly shareholding pattern as mandated by Regulation 31(1)(c) of the SEBI Listing Regulations.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.